bluebird bio (BLUE)

Bluebird Bio (BLUE) Stock Price & Analysis


BLUE Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.87 - $8.58
Previous Close$6.35
Average Volume (3M)3.77M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$139.63M
Total Debt (Recent Filing)$278.21M
Price to Earnings (P/E)-1.0
Next EarningsFeb 22, 2023
Dividend YieldN/A
EPS (TTM)-6.09
Shares Outstanding82,923,298
Standard Deviation0.17
10 Day Avg. Volume5,439,801
30 Day Avg. Volume3,766,086
Price to Book (P/B)3.20
Price to Sales (P/S)145.48
Price to Cash Flow (P/CF)5.70
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside4.55% Upside
Rating ConsensusHold
Number of Analyst Covering4



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Bluebird Bio’s price range in the past 12 months?
Bluebird Bio lowest stock price was $2.87 and its highest was $8.58 in the past 12 months.
    What is Bluebird Bio’s market cap?
    Currently, no data Available
    When is Bluebird Bio’s upcoming earnings report date?
    Bluebird Bio’s upcoming earnings report date is Feb 22, 2023 which is in 20 days.
      How were Bluebird Bio’s earnings last quarter?
      Bluebird Bio released its earnings results on Nov 07, 2022. The company reported -$0.94 earnings per share for the quarter, beating the consensus estimate of -$1.117 by $0.177.
        Is Bluebird Bio overvalued?
        According to Wall Street analysts Bluebird Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Bluebird Bio pay dividends?
          Bluebird Bio pays a Notavailable dividend of $8.88 which represents an annual dividend yield of N/A. See more information on Bluebird Bio dividends here
            What is Bluebird Bio’s EPS estimate?
            Bluebird Bio’s EPS estimate is -$0.43.
              How many shares outstanding does Bluebird Bio have?
              Bluebird Bio has 102,923,300 shares outstanding.
                What happened to Bluebird Bio’s price movement after its last earnings report?
                Bluebird Bio reported an EPS of -$0.94 in its last earnings report, beating expectations of -$1.117. Following the earnings report the stock price went up 11.093%.
                  Which hedge fund is a major shareholder of Bluebird Bio?
                  Among the largest hedge funds holding Bluebird Bio’s share is Woodline Partners LP. It holds Bluebird Bio’s shares valued at 7M.


                    Bluebird Bio Stock Smart Score

                    The Bluebird Bio stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    bluebird bio

                    bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.


                    Forecast EPS vs Actual EPS

                    Similar Stocks
                    Price & Change
                    ADMA Biologics
                    Tango Therapeutics
                    Mersana Therapeutics

                    Popular Stocks

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis